WebMar 31, 2024 · Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU ... WebAug 27, 2024 · posted on 2024-08-27, 17:35 authored by Dae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, Hiroshi Isobe, Ming-Shyan Huang, Carlos H. Barrios, Adnan …
K-ras Mutation Subtypes in NSCLC and Associated Co …
WebChristian Roesel, Stefan Welter, Karl-Otto Kambartel, Gerhard Weinreich, Thomas Krbek, Monika Serke, Mohammed Ibrahim, Yazan Alnajdawi, Till Plönes, Clemens Aigner. "Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis." Journal of Thoracic Disease 12.3 (2024) 466-476 WebMay 28, 2024 · 9050 Background: Recently reported, extended follow-up data from KEYNOTE-024 or -010 indicates that non-small-cell lung cancer (NSCLC) patients can experience long-term benefit from immunotherapy irrespective of discontinuation (per protocol: 35 cycles ∼24 months) or type of response in computed tomography (CT). … stay flow starch
Prognostic markers in resected large cell neuroendocrine
WebBackground: Patient selection, dosing regimens and resistance mechanisms for immune checkpoint inhibitor combination therapy remain unmet medical needs in lung cancer. Combining blockade of PD-1 and CTLA-4 can be more effective than monotherapy but is accompanied by an increase in toxicity. Thus, to circumvent unnecessary toxicity it is of … WebMay 30, 2024 · e20664 Background: Fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in … WebKarl-Otto Kambartel's 6 research works with 18 citations and 387 reads, including: Complete metabolic response in advanced non-small cell lung cancer patients with … stay flush mounts